RESUMO
BACKGROUND: Maintenance hemodialysis (MHD) patients reportedly display reduced daily physical activity (DPA) and physical performance. Low daily physical activity and decreased physical performance are each associated with worse outcomes in chronic kidney disease patients. Although daily physical activity and physical performance might be expected to be related, few studies have examined such relationships in MHD patients, and methods for examining daily physical activity often utilized questionnaires rather than activity monitors. We hypothesized that daily physical activity and physical performance are reduced and correlated with each other even in relatively healthier MHD patients. METHODS: Daily physical activity, 6-min walk distance (6-MWT), sit-to-stand, and stair-climbing tests were measured in 72 MHD patients (32 % diabetics) with limited comorbidities and 39 normal adults of similar age and gender mix. Daily physical activity was examined by a physical activity monitor. The human activity profile was also employed. RESULTS: Daily physical activity with the activity monitor, time-averaged over 7 days, and all three physical performance tests were impaired in MHD patients, to about 60-70 % of normal values (p < 0.0001 for each measurement). Human activity profile scores were also impaired (p < 0.0001). MHD patients spent more time sleeping or in marked physical inactivity (p < 0.0001) and less time in ≥ moderate activity (p < 0.0001). These findings persisted when comparisons to normals were restricted to men or women separately. After adjustment, daily physical activity correlated with 6-MWT but not the two other physical performance tests. Human activity profile scores correlated more closely with all three performance tests than did DPA. CONCLUSIONS: Even in relatively healthy MHD patients, daily physical activity and physical performance are substantially impaired and correlated. Whether training that increases daily physical activity or physical performance will improve clinical outcome in MHD patients needs to be examined.
RESUMO
Polyunsaturated fatty acid metabolism is governed primarily by two enzymes, prostaglandin H synthase and lipoxygenase. The crystal structure of the metastable product-oxidized purple form of soybean lipoxygenase-3 was determined at 2.0 A resolution. The data reveal that the chromophore corresponds to an iron-peroxide complex, a potential intermediate in the catalyzed reaction. A significant alteration of the iron site accompanies the formation of the complex. The structure, the first for a fatty acid-lipoxygenase complex, also reveals an unexpected mode of binding, and identifies amino acid residues that may play significant roles in catalysis, regio- and stereoselectivity.
Assuntos
Lipoxigenase/química , Proteínas de Plantas/química , Sítios de Ligação , Catálise , Cristalografia por Raios X , Espectroscopia de Ressonância de Spin Eletrônica , Compostos Férricos/química , Compostos Férricos/metabolismo , Ácidos Linoleicos/química , Ácidos Linoleicos/metabolismo , Peróxidos Lipídicos/química , Peróxidos Lipídicos/metabolismo , Lipoxigenase/metabolismo , Modelos Moleculares , Peróxidos/química , Peróxidos/metabolismo , Proteínas de Plantas/metabolismo , Conformação Proteica , Glycine max/enzimologia , Espectrofotometria UltravioletaRESUMO
Testosterone increases muscle mass and strength and regulates other physiological processes, but we do not know whether testosterone effects are dose dependent and whether dose requirements for maintaining various androgen-dependent processes are similar. To determine the effects of graded doses of testosterone on body composition, muscle size, strength, power, sexual and cognitive functions, prostate-specific antigen (PSA), plasma lipids, hemoglobin, and insulin-like growth factor I (IGF-I) levels, 61 eugonadal men, 18-35 yr, were randomized to one of five groups to receive monthly injections of a long-acting gonadotropin-releasing hormone (GnRH) agonist, to suppress endogenous testosterone secretion, and weekly injections of 25, 50, 125, 300, or 600 mg of testosterone enanthate for 20 wk. Energy and protein intakes were standardized. The administration of the GnRH agonist plus graded doses of testosterone resulted in mean nadir testosterone concentrations of 253, 306, 542, 1,345, and 2,370 ng/dl at the 25-, 50-, 125-, 300-, and 600-mg doses, respectively. Fat-free mass increased dose dependently in men receiving 125, 300, or 600 mg of testosterone weekly (change +3.4, 5.2, and 7.9 kg, respectively). The changes in fat-free mass were highly dependent on testosterone dose (P = 0.0001) and correlated with log testosterone concentrations (r = 0.73, P = 0.0001). Changes in leg press strength, leg power, thigh and quadriceps muscle volumes, hemoglobin, and IGF-I were positively correlated with testosterone concentrations, whereas changes in fat mass and plasma high-density lipoprotein (HDL) cholesterol were negatively correlated. Sexual function, visual-spatial cognition and mood, and PSA levels did not change significantly at any dose. We conclude that changes in circulating testosterone concentrations, induced by GnRH agonist and testosterone administration, are associated with testosterone dose- and concentration-dependent changes in fat-free mass, muscle size, strength and power, fat mass, hemoglobin, HDL cholesterol, and IGF-I levels, in conformity with a single linear dose-response relationship. However, different androgen-dependent processes have different testosterone dose-response relationships.
Assuntos
Composição Corporal/efeitos dos fármacos , Músculo Esquelético/efeitos dos fármacos , Testosterona/farmacologia , Adulto , Antagonistas de Androgênios/farmacologia , Água Corporal/fisiologia , Relação Dose-Resposta a Droga , Método Duplo-Cego , Exercício Físico/fisiologia , Hormônio Liberador de Gonadotropina/agonistas , Humanos , Fator de Crescimento Insulin-Like I/metabolismo , Hormônio Luteinizante/sangue , Masculino , Músculo Esquelético/anatomia & histologia , Músculo Esquelético/fisiologia , Fenômenos Fisiológicos da Nutrição , Comportamento Sexual/efeitos dos fármacos , Testosterona/antagonistas & inibidores , Testosterona/sangueRESUMO
Diverticular disease is a common medical problem seen in Western society. Outpatient management with close observation is appropriate for the majority of patients. Established criteria for hospitalization and treatment of diverticulitis can help to reduce medical costs and length of stay. Minimally invasive techniques such as computed tomography-guided drainage of diverticular abscess can expedite medical and surgical treatment.
Assuntos
Doença Diverticular do Colo , Divertículo do Colo , Doença Diverticular do Colo/diagnóstico , Doença Diverticular do Colo/terapia , Divertículo do Colo/diagnóstico , Divertículo do Colo/terapia , HumanosRESUMO
Tyrosine (Tyr) is an essential amino acid in phenylketonuria (PKU) because of the limited hydroxylation of phenylalanine (Phe) to Tyr. The recommended intakes for Tyr in PKU are at least five times the recommended phenylalanine intakes. This suggests that Phe and Tyr contribute approximately 20 and 80%, respectively, of the aromatic amino acid (AAA) requirement (REQ). In animals and normal humans, dietary Tyr was shown to spare 40-50% of the Phe requirement, proportions that reflect dietary and tissue protein composition. We tested the hypothesis that the Tyr REQ in PKU would account for 45% of the total AAA REQ by indicator amino acid oxidation (IAAO). Tyr REQ was determined in five children with PKU by examining the effect of varying dietary Tyr intake on lysine oxidation and the appearance of (13)CO(2) in breath (F(13)CO(2)) under dietary conditions of adequate energy, protein (1.5 g x kg(-1) x day(-1)), and phenylalanine (25 mg x kg(-1) x day(-1)). Lysine oxidation and F(13)CO(2) were determined using a primed 4-h oral equal-dose infusion of L-[1-(13)C]lysine. Lysine oxidation and F(13)CO(2) decreased linearly as Tyr intake increased, to a break point that was interpreted as the mean dietary Tyr requirement (16.3 and 19.2 mg x kg(-1) x day(-1), respectively). At Tyr intakes of >16.3 and 19.2 mg x kg(-1) x day(-1), lysine oxidation and F(13)CO(2), respectively, were low and constant. This represents 40.4 and 44.4%, respectively, of the total AAA intake. The current recommendations for Tyr intake in PKU patients appear to be overestimated by a factor of approximately 5. This study is the first application of the IAAO technique in a pediatric population and in humans with an inborn error of metabolism.
Assuntos
Lisina/metabolismo , Necessidades Nutricionais , Fenilcetonúrias/fisiopatologia , Tirosina/administração & dosagem , Testes Respiratórios , Dióxido de Carbono/análise , Isótopos de Carbono , Criança , Dieta , Feminino , Humanos , Hidroxilação , Masculino , Oxirredução , Fenilalanina/administração & dosagem , Fenilalanina/metabolismoRESUMO
The causes of colonic obstruction are protean. Less common is the diagnosis of eosinophilic gastroenteritis (EGE). EGE is more common as a cause of more proximal bowel obstruction. To our knowledge, this case represents one of the only reported cases of such a lesion causing obstruction in the cecum.
Assuntos
Doenças do Ceco/diagnóstico , Eosinofilia/diagnóstico , Gastroenterite/diagnóstico , Obstrução Intestinal/diagnóstico , Idoso , Doenças do Ceco/patologia , Doenças do Ceco/cirurgia , Ceco/patologia , Ceco/cirurgia , Eosinofilia/patologia , Eosinofilia/cirurgia , Feminino , Gastroenterite/patologia , Gastroenterite/cirurgia , Humanos , Obstrução Intestinal/patologia , Obstrução Intestinal/cirurgiaRESUMO
Urine sampling of the free amino acid pool serves to reflect plasma enrichment and is used as a noninvasive means to determine isotope enrichment in studies of amino acid metabolism. We determined the effect of D-[13C]phenylalanine and D-[13C]lysine content of tracers on urinary amino acid enrichment following oral infusion of L-[13C]phenylalanine in 18 preterm infants and L-[1-(13)C]lysine in seven healthy adult females. Urinary [13C]phenylalanine enrichment was higher (P < .0001) for L-[13C]phenylalanine containing 0.4% D-[13C]phenylalanine (28.6 +/- 7.1) versus L-[1-(13)C]phenylalanine that contained undetectable D-[13C]phenylalanine (10.2 +/- 1.5). D-[13C]phenylalanine, measured by chiral column gas chromatography-mass spectrometry (GC-MS), accounted for 10% to 30% (20.5% +/- 7%) of total phenylalanine in the urine of infants who received 0.4% D-[13C]phenylalanine, and was absent from the urine of infants receiving tracer with undetectable [13C]phenylalanine. Urinary L-[13C]phenylalanine enrichment did not differ between tracer groups (9.8 +/- 1.5 and 9.8 +/- 2.5). In adult females, the use of L-[1-(13)C]lysine (1.6% D-lysine) resulted in a higher (P < .02) urine total L,D-[13C]lysine enrichment compared with plasma enrichment (40.8 +/- 4.1 v 11.1 +/- 0.7). This study demonstrates the significant presence of D-[13C]amino acids in urine that originate as contaminants from commercially manufactured tracers, as a result of renal tubular discrimination of D-amino acids. A tracer containing detectable amounts of D-[13C]isomer cannot be recommended for any study in which urine will be used to reflect enrichment in the arterial plasma pool.
Assuntos
Isótopos de Carbono , Lisina/química , Lisina/urina , Fenilalanina/química , Fenilalanina/urina , Administração Oral , Adulto , Aminoácidos/urina , Fatores de Confusão Epidemiológicos , Feminino , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Lactente , Recém-Nascido , Recém-Nascido Prematuro , Lisina/administração & dosagem , Fenilalanina/administração & dosagem , EstereoisomerismoRESUMO
Aging is associated with a decrease in fat-free mass, an increase in fat mass, and progressive impairment of muscle function and performance. Diminishing anabolic hormone levels and progressive declines in muscle protein turnover contribute to the multifactorial pathophysiology of age-associated sarcopenia. The potential effects of anabolic hormone replacement on body composition and functional capacity are only beginning to be studied.
RESUMO
The primed, continuous intravenous infusion of amino acids labeled with 13C together with measurement of isotopic enrichment in plasma is commonly used to study amino acid metabolism. However, a less invasive, oral infusion that also produces an isotopic steady state in CO2 and urine would be useful, particularly for pediatric studies. We measured the 13C enrichments of expired CO2, plasma and urine free phenylalanine and lysine and estimated flux and oxidation rates in adult humans (n = 12) who received a 4-h oral, primed, equal dose infusion of either L-[1-13C]phenylalanine, L-[1-13C]lysine (D-lysine = 1.6%) or L-[1-13C]lysine (D-lysine = 0.2%). Steady fed state conditions were established by feeding subjects eight hourly meals beginning 4 h before the start of the oral infusion protocol. Isotopic plateau in CO2, plasma and urine was achieved within 120 min of phenylalanine or lysine infusion. At isotopic plateau, the mean ratio of plasma to urine enrichment was 1.0 +/- 0.04 (SEM), 0. 39 +/- 0.03 and 0.97 +/- 0.02 for L-[1-13C]phenylalanine, L-[1-13C]lysine (D-lysine = 1.6%) and L-[1-13C]lysine (D-lysine= 0. 2%), respectively. There was good agreement between isotopic enrichment in plasma and urine for L-[1-13C]phenylalanine and L-[1-13C]lysine (D-lysine = 0.2%). However, use of L-[1-13C]lysine (D-lysine = 1.6%) resulted in significantly higher enrichment in urine, probably due to renal tubular discrimination of D-lysine. Mean flux rates for phenylalanine and lysine were consistent with the literature. Thus, the oral, primed, equal dose infusion produces the isotopic steady-state condition required for amino acid flux and oxidation determination within an 8-h period.
Assuntos
Alimentos , Lisina/metabolismo , Fenilalanina/metabolismo , Adulto , Testes Respiratórios , Dióxido de Carbono/análise , Isótopos de Carbono , Feminino , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Cinética , Lisina/administração & dosagem , Masculino , Oxirredução , Fenilalanina/administração & dosagemRESUMO
Testosterone-induced nitrogen retention in castrated male animals, eunuchoidal men, pre-pubertal boys and women, and the sex-related differences in the size of the muscles between male and female animals, have been cited as evidence that testosterone has anabolic effects. Recent studies have reported that replacement doses of testosterone in hypogonadal men and supraphysiological doses in eugonadal men increase fat-free mass, muscle size and strength. These effects have provided the rationale for exploring these anabolic applications in sarcopenic states. Although emerging data demonstrate modest gains in fat-free mass in HIV-infected men given replacement doses of testosterone, we do not know whether testosterone supplementation can produce clinically meaningful changes in muscle function and disease outcome in patients with wasting disorders.
Assuntos
Anabolizantes/farmacologia , Composição Corporal , Músculos/fisiologia , Testosterona/fisiologia , Anabolizantes/uso terapêutico , Composição Corporal/efeitos dos fármacos , Feminino , Humanos , Hipogonadismo/tratamento farmacológico , Masculino , Músculos/efeitos dos fármacos , Músculos/patologia , Testosterona/sangue , Síndrome de Emaciação/tratamento farmacológicoRESUMO
Humans lose weight when administered fluoxetine, an inhibitor of serotonin reuptake by nerve terminals. To determine whether increased energy expenditure contributes to this weight loss we admitted 20 nondepressed obese women to a metabolic unit where they were randomly assigned to 3 wk of a 1.76-MJ/d formula diet and either 60 mg fluoxetine/d or a placebo. Resting energy expenditure of the control subjects fell below normal after 5.6 +/- 0.6 d of energy restriction, whereas that of the fluoxetine-treated subjects increased by 4.4 +/- 1.8% (P < 0.005) within 3 d of commencing treatment. This increased resting energy expenditure then reversed and fell below normal after 9.8 +/- 0.9 d of energy restriction. Basal body temperature of the control subjects decreased insignificantly during the period of energy restriction, but that of the fluoxetine-treated subjects increased by 0.28 +/- 0.10 degrees C (P < 0.05) within 3 d of commencing diet and drug treatment. Urinary norepinephrine excretion and the serum triiodothyronine concentration decreased equally in both groups. Despite identical energy intakes and equal nitrogen balance, the fluoxetine-treated subjects lost weight faster than the control subjects during the final week of energy restriction (P < 0.05). We propose that serotonin reuptake inhibition increases energy expenditure by increasing basal body temperature.
Assuntos
Temperatura Corporal/efeitos dos fármacos , Metabolismo Energético/efeitos dos fármacos , Fluoxetina/farmacologia , Obesidade/metabolismo , Adulto , Temperatura Corporal/fisiologia , Quimioterapia Adjuvante , Dieta Redutora , Método Duplo-Cego , Metabolismo Energético/fisiologia , Feminino , Fluoxetina/uso terapêutico , Humanos , Norepinefrina/urina , Obesidade/dietoterapia , Obesidade/tratamento farmacológico , Descanso/fisiologia , Antagonistas da Serotonina/farmacologia , Tiroxina/sangue , Tri-Iodotironina/sangue , Redução de Peso/efeitos dos fármacosAssuntos
Emergências , Pediatria , Preparações Farmacêuticas/administração & dosagem , Criança , HumanosRESUMO
The SITE instrument appears to combine advantages of other instruments previously described. It meets the proposed objectives of an efficient cutter where tissue is removed at the front end of the tip. It allows the surgeon complete control of the suction and reflux systems. The instrument is of a simple modular dsign. A fiber optic attachment is available. It is dependable and safe.